First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma

The aim of the investigation was to estimate Vero-Fludarabine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. We report the activity of three combinations of Vero-Fludarabine, one with cyclophosphamide (Vero-FluCy), the second with cyclophosphamide plus rubida (Vero-FLUCYr) and 3^rd with rituximab (VeroFCR). For patients with chronic lymphocytic leukemia who received Vero-FluCy the overall response rate was 66.6%. Of the 9 patients, who received Vero-FluCy, 33.3% achieved complete remission and 33.3% partial remission. For patients with follicular lymphoma grades 1 and 2 who received Vero-FLUCYr or VeroFCR the overall response rate was 100%. The treatment was well tolerated. Hematologic toxicity included neutropenia and thrombocytopenia. 24% patients who received Vero-FluCy were complicated by infections. Nonhematologic toxicity was mild.

We conclude that Vero-Fludarabine is an effective treatment in previously untreated or in pretreated patients with chronic lymphocytic leukemia and follicular lymphomas.